Emily Hill serves as the Chief Financial Officer at Replimune Group Inc., a clinical-stage biotechnology company focused on developing innovative oncolytic immunotherapies for cancer treatment. With a robust background in finance and biotechnology, Emily brings a wealth of experience to her role at Replimune. She joined the company in 2018 and has been instrumental in guiding the company through significant growth stages, including multiple rounds of financing and the advancement of their clinical trials. Prior to her tenure at Replimune, Emily held various senior financial positions at other biotech firms, where she honed her skills in strategic financial planning and investor relations. Her career also includes a stint at a leading global investment bank, where she advised on numerous high-profile mergers and acquisitions within the life sciences sector. Emily's expertise in navigating complex financial landscapes has been a key asset for Replimune, enabling the company to secure substantial investments and forge strategic partnerships. As CFO, Emily oversees all aspects of Replimune's financial strategy, including budgeting, forecasting, and financial reporting. Her leadership has been pivotal in maintaining the company's financial health while supporting its mission to bring groundbreaking cancer therapies to market. Under her guidance, Replimune has successfully expanded its clinical programs and strengthened its position in the competitive biotech industry. Emily's dedication to the company's vision and her strategic financial acumen continue to drive Replimune's growth and success.